Free Trial
NASDAQ:EDIT

Editas Medicine Q2 2025 Earnings Report

Editas Medicine logo
$3.01 +0.01 (+0.33%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$3.00 0.00 (-0.17%)
As of 09/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Editas Medicine EPS Results

Actual EPS
-$0.63
Consensus EPS
-$0.41
Beat/Miss
Missed by -$0.22
One Year Ago EPS
N/A

Editas Medicine Revenue Results

Actual Revenue
$3.58 million
Expected Revenue
$1.81 million
Beat/Miss
Beat by +$1.77 million
YoY Revenue Growth
N/A

Editas Medicine Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Editas Medicine's Q3 2025 earnings is scheduled for Monday, November 3, 2025, with a conference call scheduled at 7:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Editas Medicine Earnings Headlines

Editas Medicine (EDIT) Receives a Hold from JonesTrading
China’s message to Trump
Did China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of military power. Fighter jets, tanks, AI-guided drones — all paraded under the red flag, in front of Vladimir Putin, Kim Jong Un, and more than two dozen world leaders.tc pixel
Can Editas Medicine (NASDAQ:EDIT) Afford To Invest In Growth?
Editas Medicine, Inc. - Special Call
See More Editas Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Editas Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Editas Medicine and other key companies, straight to your email.

About Editas Medicine

Editas Medicine (NASDAQ:EDIT) is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach. In oncology, Editas is advancing programs that modify immune cells to enhance anti-tumor activity. Strategic collaborations with pharmaceutical partners, including a 2015 agreement with Allergan (now part of AbbVie) for ocular disease programs and a partnership with Bristol Myers Squibb’s Juno Therapeutics for engineered cell therapy, have supported the expansion of its research footprint.

Editas Medicine operates primarily in North America, conducting clinical studies in the United States and collaborating with academic and clinical research centers globally. The company was co-founded by leading genome scientists, including Feng Zhang of the Broad Institute, and is led by President and CEO James Mullen Jr., whose experience spans leadership roles at several biotechnology and pharmaceutical firms.

With a mission to develop precise, durable treatments for patients with severe genetic diseases, Editas continues to advance its proprietary gene-editing platforms through clinical development and strategic partnerships. The company remains committed to rigorous scientific validation and regulatory engagement as it seeks to bring first-in-class genomic medicines to the clinic.

View Editas Medicine Profile

More Earnings Resources from MarketBeat